Clear Search sequence regions
Bookmark Forward

QuickView for Bleomycin (compound)


PubChem
Name: Bleomycin
PubChem Compound ID: 11980859
Description: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Molecular formula: C110H168N37O42S5+
Molecular weight: 2841.07 g/mol
Synonyms:
NSC125066; Bleomycin sulfate; 11056-06-7
DrugBank
Identification
Name: Bleomycin
Name (isomeric): DB00290
Drug Type: small molecule
Description: A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
Synonyms:
Bleomycin A2; Bleomycinum [INN-Latin]; Bleomycin B2; BLM; Bleomycine [INN-French]; Bleomicina [INN-Spanish]; Bleomycin sulfate; Bleomicin; Bleocin
Brand: Blenoxane, Bleo
Category: Antimetabolites, Antibiotics, Antineoplastic
CAS number: 11056-06-7
Pharmacology
Indication: For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Pharmacology:
Bleomycin is an antibiotic which has been shown to have antitumor activity. Bleomycin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of mitomycin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed. Bleomycin...
show more »
Mechanism of Action:
Although the exact mechanism of action of bleomycin is unknown, available evidence would seem to indicate that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. It is believed that bleomycin c...
show more »
Absorption: Systemic absorption is approximately 45%.
Protein binding: 1%
Biotransformation: Hepatic
Route of elimination: It was reported that patients with moderately severe renal failure excreted less than 20% of the dose in the urine.
Half Life: 115 minutes
Toxicity: Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction.
Affected organisms: Humans and other mammals
Interactions
Drug interaction:
NatalizumabImmunosuppressants like bleomycin may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. Patients receiving natalizumab should not use concurrent immunosuppressants.
TrastuzumabTrastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
FosphenytoinThe antineoplasic agent decreases the effect of hydantoin
TacrolimusTacrolimus (Topical) may enhance the adverse/toxic effect of Immunosuppressants. Avoid use of tacrolimus ointment in patients receiving immunosuppressants.
LeflunomideImmunosuppressants like bleomycin may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased. Consider eliminating the use of a leflunomide loading dose in patients who are receiving other immunosuppressants in order to reduce the risk for serious adverse events such as hematologic toxicity.
show more »

Targets


Enzymes